MK-8228 (Letermovir) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)
Status: | Recruiting |
---|---|
Conditions: | Infectious Disease, Hospital |
Therapuetic Areas: | Immunology / Infectious Diseases, Other |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 3/12/2016 |
Start Date: | June 2014 |
End Date: | January 2017 |
Contact: | Toll Free Number |
Phone: | 1-888-577-8839 |
A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients
The study will evaluate the efficacy and safety of MK-8228 for the prevention of
clinically-significant CMV infection in adult, CMV-seropositive recipients of allogeneic
hematopoietic stem cell transplant. The hypothesis being tested is that MK-8228 is superior
to placebo in the prevention of clinically-significant CMV infection through 24 weeks after
transplant.
clinically-significant CMV infection in adult, CMV-seropositive recipients of allogeneic
hematopoietic stem cell transplant. The hypothesis being tested is that MK-8228 is superior
to placebo in the prevention of clinically-significant CMV infection through 24 weeks after
transplant.
Inclusion Criteria:
- Has documented seropositivity for CMV within 1 year before hematopoietic stem cell
transplant (HSCT)
- Receiving first allogeneic HSCT (bone marrow, peripheral blood stem cell, or cord
blood transplant)
- Female or male participant who is not of reproductive potential, or, if of
reproductive potential, agrees to true abstinence or to use (or have their partner
use) 2 acceptable methods of birth control from the time of consent through 90 days
after the last dose of study drug
- Able to read, understand, and complete questionnaires and diaries
Exclusion Criteria:
- Received a previous allogeneic HSCT (previous autologous HSCT is acceptable)
- History of CMV end-organ disease within 6 months before randomization
- Has evidence of CMV viremia (if tested) at any time from either signing of the
Informed Consent Form or the HSCT procedure, whichever is earlier, until the time of
randomization.
- Received the following within 7 days before screening or plans to receive during the
study: ganciclovir, valganciclovir, foscarnet, acyclovir, valacyclovir, or
famciclovir
- Received the following within 30 days before screening or plan to receive during the
study: cidofovir, CMV hyper-immune globulin, any investigational CMV antiviral agent
or biological therapy
- Has suspected or known hypersensitivity to ingredients of MK-8228 (letermovir)
formulations
- Has severe hepatic insufficiency within 5 days before randomization
- Has end-stage renal impairment
- Has an uncontrolled infection on the day of randomization
- Requires mechanical ventilation or is hemodynamically unstable at the time of
randomization
- Has documented positive results for human immunodeficiency virus (HIV) antibody,
hepatitis C virus (HCV) antibody with detectable HCV ribonucleic acid, or hepatitis B
surface antigen (HBsAg) within 90 days before randomization
- Has active solid tumor malignancies with the exception of localized basal cell or
squamous cell skin cancer or the condition under treatment (for example, lymphoma)
- Is pregnant or expecting to conceive, is breastfeeding, or plans to breastfeed from
the time of consent through 90 days after the last dose of study drug
- Is expecting to donate eggs or sperm from the time of consent through 90 days after
the last dose of study drug
- Has participated in a study with an unapproved investigational compound (monoclonal
antibodies are excepted) or device within 28 days of the first dose of study drug
- Has previously participated in a MK-8228 (letermovir) study
- Has, is, or is planning (during the study) to participate in any study involving
administration of a CMV vaccine or another CMV investigational agent
- Is a user of recreational or illicit drugs or has a recent history (<=1 year) of drug
or alcohol abuse or dependence
We found this trial at
19
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials